Literature DB >> 33068196

Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution.

Xiaoxian Li1, Zhongliang Ma2, Toncred M Styblo3, Cletus A Arciero3, Haibo Wang2, Michael A Cohen4.   

Abstract

BACKGROUND: The management of high-risk breast lesions diagnosed on image-guided core biopsy remains controversial. We implemented a high-risk breast conference attended by breast pathologists, imagers, and surgeons to prospectively review all contemporary cases in order to provide a consensus recommendation to either surgically excise or follow on imaging at 6-month intervals for a minimum of 2 years.
METHODS: Between May, 2015 and June, 2019, 127 high-risk lesions were discussed. Of these 127 cases, 116 had concordant radiology-pathology (rad-path) findings. The remaining 11 patients had discordant rad-path findings. Of the 116 concordant cases, 6 were excluded due to lack of the first imaging follow-up until analysis. Of the remaining 110 patients, 43 had atypical ductal hyperplasia (ADH), 12 had lobular carcinoma in situ (LCIS), 19 had atypical lobular hyperplasia (ALH), 33 had radial scar (RS), 2 had flat epithelial atypia (FEA), and 1 had mucocele-like lesion (ML). We recommended excision for ADH if there were > 2 ADH foci or < 90% of the associated calcifications were removed. For patients with LCIS or ALH, we recommended excision if the LCIS or ALH was associated with microcalcifications or the LCIS was extensive. We recommended excision of RS when < 1/2 of the lesion was biopsied. We recommended all patients with FEA and ML for 6-month follow-up.
RESULTS: Following conference-derived consensus for excision, of the 27 ADH excised, 9 were upgraded to invasive carcinoma or ductal carcinoma in situ. Of the six LCIS cases recommended for excision, none were upgraded. Nine excised radial scars revealed no upgrades. Additionally, 3 patients with ADH, 2 with ALH, 1 with LCIS, and 2 with RS underwent voluntary excision, and none were upgraded. All other patients (13 with ADH, 5 LCIS, 17 ALH, 22 RS, 2 FEA and 1 ML) were followed with imaging, and none revealed evidence of disease progression during follow-up (187-1389 days). All 11 rad-path discordant cases were excised with 2 upgraded to carcinoma.
CONCLUSIONS: The results of this prospective study indicate that high-risk breast lesions can be successfully triaged to surgery versus observation following establishment of predefined firm guidelines and performance of rigorous rad-path correlation.

Entities:  

Keywords:  Atypical lobular hyperplasia; Flat epithelial atypia; High-risk breast lesion; Lobular carcinoma in situ; Mucocele-like lesion; Radial scar

Mesh:

Year:  2020        PMID: 33068196     DOI: 10.1007/s10549-020-05977-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  59 in total

1.  Is surgical excision necessary for focal atypical ductal hyperplasia found at stereotactic vacuum-assisted breast biopsy?

Authors:  Peter R Eby; Jennifer E Ochsner; Wendy B DeMartini; Kimberly H Allison; Sue Peacock; Constance D Lehman
Journal:  Ann Surg Oncol       Date:  2008-08-12       Impact factor: 5.344

2.  Atypical hyperplastic lesions of the female breast. A long-term follow-up study.

Authors:  D L Page; W D Dupont; L W Rogers; M S Rados
Journal:  Cancer       Date:  1985-06-01       Impact factor: 6.860

3.  Upgrade of high-risk breast lesions detected on mammography in the Breast Cancer Surveillance Consortium.

Authors:  Tehillah S Menes; Robert Rosenberg; Steven Balch; Shabnam Jaffer; Karla Kerlikowske; Diana L Miglioretti
Journal:  Am J Surg       Date:  2013-10-07       Impact factor: 2.565

4.  Patients with benign papilloma diagnosed on core biopsies and concordant pathology-radiology findings can be followed: experiences from multi-specialty high-risk breast lesion conferences in an academic center.

Authors:  Zhongliang Ma; Cletus A Arciero; Toncred M Styblo; Haibo Wang; Michael A Cohen; Xiaoxian Li
Journal:  Breast Cancer Res Treat       Date:  2020-07-23       Impact factor: 4.872

5.  Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: a report from the Breast Cancer Surveillance Consortium.

Authors:  Kimberly H Allison; Linn A Abraham; Donald L Weaver; Anna N A Tosteson; Heidi D Nelson; Tracy Onega; Berta M Geller; Karla Kerlikowske; Patricia A Carney; Laura E Ichikawa; Diana S M Buist; Joann G Elmore
Journal:  Cancer       Date:  2015-01-20       Impact factor: 6.860

6.  Atypical ductal hyperplasia diagnosis by directional vacuum-assisted stereotactic biopsy of breast microcalcifications. Considerations for surgical excision.

Authors:  Nour Sneige; Sung C Lim; Gary J Whitman; Savitri Krishnamurthy; Aysegul A Sahin; Terry L Smith; Carol B Stelling
Journal:  Am J Clin Pathol       Date:  2003-02       Impact factor: 2.493

7.  Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary?

Authors:  Michelle C Foster; Mark A Helvie; Nancy E Gregory; Murray Rebner; Alexis V Nees; Chintana Paramagul
Journal:  Radiology       Date:  2004-04-22       Impact factor: 11.105

8.  A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast.

Authors:  F A Tavassoli; H J Norris
Journal:  Cancer       Date:  1990-02-01       Impact factor: 6.860

9.  Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease.

Authors:  D L Page; T E Kidd; W D Dupont; J F Simpson; L W Rogers
Journal:  Hum Pathol       Date:  1991-12       Impact factor: 3.466

10.  Papilloma diagnosed on core biopsies has a low upgrade rate.

Authors:  Xiaoxian Li; Michael Aho; Mary S Newell; Kelly Clifford; Jay G Patel; Stephanie Jou; Michael A Cohen
Journal:  Clin Imaging       Date:  2019-12-03       Impact factor: 2.420

View more
  1 in total

1.  High-risk lesions in the breast diagnosed by MRI-guided core biopsy: upgrade rates and features associated with malignancy.

Authors:  Eumee Cha; Emily B Ambinder; Eniola T Oluyemi; Lisa A Mullen; Babita Panigrahi; Joanna Rossi; Philip A Di Carlo; Kelly S Myers
Journal:  Breast Cancer Res Treat       Date:  2022-10-15       Impact factor: 4.624

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.